Table 1.

Seric concentration of s-sortilin and sortilin-derived peptide in healthy controls, MDD before and after AD treatment or ECT.

Seric [peptide]	Healthy controls	MDD/controls	12 week AD treatment	AD treatment-resistant	AD treatment-resistant+ECT
S-sortilin∗	Basal level (n = 216)	Increased (n = 152)	Remains increased (n = 56)	n.d.	n.d.
Sortilin-derived peptide PE∗∗	Basal level (n = 49)	Decreased (n = 37)	Restores basal level (n = 37)	Basal level (n = 49)	Increased (R) (n = 35)

^∗From Buttenschon et al. (2015, 2017). ^∗∗From Devader et al. (2017) and Roulot et al. (2018). MDD, major depressive disorder; AD, antidepressant; R, responders; ECT, electroconvulsive therapy; n.d., not determined.